96 related articles for article (PubMed ID: 10138581)
1. Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis.
Connelly JF
Hosp Pharm; 1994 Nov; 29(11):992, 996-8, 1001. PubMed ID: 10138581
[TBL] [Abstract][Full Text] [Related]
2. Pharmacist intervention program focused on i.v. ranitidine therapy.
Santora J; Kitrenos JG; Green ER
Am J Hosp Pharm; 1990 Jun; 47(6):1346-9. PubMed ID: 2368729
[TBL] [Abstract][Full Text] [Related]
3. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
Dannenhoffer MA; Slaughter RL; Hunt SN
Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
[TBL] [Abstract][Full Text] [Related]
4. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions.
Pearson VE; King LM
Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189
[TBL] [Abstract][Full Text] [Related]
5. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy.
Caldwell RD; Davis SK
Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375
[TBL] [Abstract][Full Text] [Related]
6. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
[TBL] [Abstract][Full Text] [Related]
7. The use of intravenous H2-receptor antagonists in a tertiary care hospital.
Dettmer RM; Riley TH; Byfield F; Green PH
Am J Gastroenterol; 1999 Dec; 94(12):3473-7. PubMed ID: 10606306
[TBL] [Abstract][Full Text] [Related]
8. Using serum creatinine concentrations to screen for inappropriate dosage of renally eliminated drugs.
Peterson JP; Colucci VJ; Schiff SE
Am J Hosp Pharm; 1991 Sep; 48(9):1962-4. PubMed ID: 1928141
[TBL] [Abstract][Full Text] [Related]
9. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit.
Chuang LC; Sutton JD; Henderson GT
Hosp Pharm; 1994 Mar; 29(3):215-8, 221. PubMed ID: 10132696
[TBL] [Abstract][Full Text] [Related]
10. Impact of a pharmacy resident on hospital length of stay and drug-related costs.
Terceros Y; Chahine-Chakhtoura C; Malinowski JE; Rickley WF
Ann Pharmacother; 2007 May; 41(5):742-8. PubMed ID: 17440008
[TBL] [Abstract][Full Text] [Related]
11. Automated administration of intermittent intravenous doses.
Lutomski DM; Schwartz-Fulton J; Rivera JO
Am J Hosp Pharm; 1985 Nov; 42(11):2514-7. PubMed ID: 4073071
[TBL] [Abstract][Full Text] [Related]
12. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study.
Ng TM; Bell AM; Hong C; Hara JM; Touchette DR; Danskey KN; Lindsay TT; Puumala SE
Ann Pharmacother; 2008 Apr; 42(4):475-82. PubMed ID: 18319393
[TBL] [Abstract][Full Text] [Related]
13. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
14. Computer program for comparing total costs of intravenous antibiotic regimens.
Parr MD; Hansen LA; Waite WW; Rapp RP
Am J Hosp Pharm; 1986 Sep; 43(9):2189-93. PubMed ID: 3766570
[TBL] [Abstract][Full Text] [Related]
15. Reducing costs by adjusting dosage intervals for intravenous ranitidine.
Holt RT; Graves LJ; Scheil E
Am J Hosp Pharm; 1990 Sep; 47(9):2068-9. PubMed ID: 2220867
[No Abstract] [Full Text] [Related]
16. Cost of computerized drug interaction screening system.
Greenlaw CW
Am J Hosp Pharm; 1981 Apr; 38(4):521-4. PubMed ID: 7282679
[TBL] [Abstract][Full Text] [Related]
17. Indicators to control drug costs in hospitals.
Mehl B
Am J Hosp Pharm; 1984 Apr; 41(4):667-75. PubMed ID: 6720708
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and financial impact of imipenem/cilastatin dosing in elderly patients based on renal function and body weight.
Ritchie DJ; Reichley RM; Canaday KL; Bailey TC
J Pharm Technol; 1993; 9(4):160-3. PubMed ID: 10128045
[TBL] [Abstract][Full Text] [Related]
19. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
Segal R; Oh T; Ben-Joseph R; Russell WL
Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin use under a reserved drug and stepdown promotion program.
Frighetto L; Martinusen SM; Mamdani F; Jewesson PJ
Can J Hosp Pharm; 1995 Feb; 48(1):35-42. PubMed ID: 10141061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
